{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T23:41:25Z","timestamp":1650584485684},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"S6","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW - Fortschritte der Medizin"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s15006-022-0876-1","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T23:04:26Z","timestamp":1650582266000},"page":"19-27","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tapentadol versus klassische     WHO-III-Opioide bei chronischen     R\u00fcckenschmerzen"],"prefix":"10.1007","volume":"164","author":[{"given":"Kai-Uwe","family":"Kern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Vogelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"T\u00f6lle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"876_CR5801","doi-asserted-by":"crossref","unstructured":"Kuntz B, Hoebel J, Fuchs J, et al. Soziale Ungleichheit und chronische R\u00fcckenschmerzen bei Erwachsenen in Deutschland. Bundesgesundheitsbl 2017;60:783-791","DOI":"10.1007\/s00103-017-2568-z"},{"key":"876_CR5805","doi-asserted-by":"crossref","unstructured":"Baron R, Binder A, Attal N, Casale R, Dickenson AH, Treede RD. Neuropathic low back pain in clinical practice. Eur J Pain 2016;20:861-873","DOI":"10.1002\/ejp.838"},{"key":"876_CR5809","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Nicht-spezifischer Kreuzschmerz - Langfassung, 2. Auflage. Version 1. 2017. https:\/\/www.leitlinien.de\/nvl\/kreuzschmerz"},{"key":"876_CR5813","doi-asserted-by":"crossref","unstructured":"Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-S120","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"876_CR5817","doi-asserted-by":"crossref","unstructured":"Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep 2013;15(9):344","DOI":"10.1007\/s11894-013-0344-2"},{"key":"876_CR5821","doi-asserted-by":"crossref","unstructured":"Drewes AM, Munkholm P, Simr\u00e9n M, et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scand J Pain 2016;11:111-122","DOI":"10.1016\/j.sjpain.2015.12.005"},{"key":"876_CR5825","doi-asserted-by":"crossref","unstructured":"Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain 2019;35:174-188","DOI":"10.1097\/AJP.0000000000000662"},{"key":"876_CR5829","doi-asserted-by":"crossref","unstructured":"Tzschentke TN, Christoph T, Schr\u00f6der W, et al. Tapentadol: mit zwei Mechanismen in einem Molek\u00fcl wirksam gegen nozizeptive und neuropathische Schmerzen. Pr\u00e4klinischer \u00dcberblick. Schmerz 2011;25:19-25","DOI":"10.1007\/s00482-010-1004-1"},{"key":"876_CR5833","doi-asserted-by":"crossref","unstructured":"Tzschentke TM, Christoph T, K\u00f6gel BY. The mu-opioid receptor agonist\/ noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: The case of tapentadol. CNS Drugs 2014;28:319-329","DOI":"10.1007\/s40263-014-0151-9"},{"key":"876_CR5837","doi-asserted-by":"crossref","unstructured":"Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract 2017;17:678-700","DOI":"10.1111\/papr.12515"},{"key":"876_CR5841","unstructured":"Federal Statistical Office of Germany (2015) German population by age and gender. https:\/\/www.statistischebibliothek.de\/mir\/servlets\/MCRFileNodeServlet\/DEHeft_derivate_00048509\/2010130157004_ergaenzt19072017.pdf1"},{"key":"876_CR5845","doi-asserted-by":"crossref","unstructured":"Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2000;95:573-585","DOI":"10.1080\/01621459.2000.10474233"},{"key":"876_CR5849","doi-asserted-by":"crossref","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-161","DOI":"10.1002\/pst.433"},{"key":"876_CR5853","doi-asserted-by":"crossref","unstructured":"Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: The matching package for R. J Stat Softw 2011:42(7):1-52","DOI":"10.18637\/jss.v042.i07"},{"key":"876_CR5866","doi-asserted-by":"crossref","unstructured":"Lamas K, Karlsson S, Nolen A, Lovheim H, Sandman PO. Prevalence of constipation among persons living in institutional geriatric-care settings - a cross-sectional study. Scand J Caring Sci 2017;31(1):157-163","DOI":"10.1111\/scs.12345"},{"key":"876_CR5870","doi-asserted-by":"crossref","unstructured":"Pinto Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011;25 (Suppl B):11B-15B","DOI":"10.1155\/2011\/125491"},{"key":"876_CR5874","doi-asserted-by":"crossref","unstructured":"Fischbach W, Malfertheiner P, Lynen Jansen P, et al. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016;54:327-363","DOI":"10.1055\/s-0042-102967"},{"key":"876_CR5878","doi-asserted-by":"crossref","unstructured":"Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterol 2016;150:1393-1407","DOI":"10.1053\/j.gastro.2016.02.031"},{"key":"876_CR5882","unstructured":"Deutsche Gesellschaft f\u00fcr Schmerzmedizin. Praxisleitlinie Opioidinduzierte Obstipation. 2019. https:\/\/www.dgs-praxisleitlinien.de\/index.php\/leitlinien\/oic"},{"key":"876_CR5886","doi-asserted-by":"crossref","unstructured":"Chokhavatia S, John ES, Bridgeman MB, Dixit D. Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation. Drugs Aging 2016;33:557-574.","DOI":"10.1007\/s40266-016-0381-2"},{"key":"876_CR5892","doi-asserted-by":"crossref","unstructured":"Coyne KS, Margolis MK, Yeomans K, et al. Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time. Pain Med 2015;16:1551-1565","DOI":"10.1111\/pme.12724"},{"key":"876_CR5896","doi-asserted-by":"crossref","unstructured":"Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res 2014;6:269-281","DOI":"10.2147\/CEOR.S61602"},{"key":"876_CR5900","doi-asserted-by":"crossref","unstructured":"Nordahl Christensen H, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain 2016;11:104-110","DOI":"10.1016\/j.sjpain.2015.12.007"},{"key":"876_CR5905","doi-asserted-by":"crossref","unstructured":"Andresen V, Banrji V, Hall G, Lass A, Emmanuel AV. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United European Gastroenterol J 2018;6:1254-1266","DOI":"10.1177\/2050640618786145"},{"key":"876_CR5910","doi-asserted-by":"crossref","unstructured":"H\u00e4user W, Bock F, H\u00fcppe M, et al. Empfehlungen der zweiten Aktualisierung der Leitlinie LONTS. Langzeitanwendung von Opioiden bei chronischen nicht-tumorbedingten Schmerzen. Schmerz 2020;34:204-244","DOI":"10.1007\/s00482-020-00472-y"},{"key":"876_CR5914","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Lissner S. Opiatinduzierte Obstipation - Mechanismen, Relevanz und Behandlung. Dtsch Med Wochenschr 2013;138:2207-2211","DOI":"10.1055\/s-0033-1349447"},{"key":"876_CR5930","doi-asserted-by":"crossref","unstructured":"Santos J, Alarc\u00e3o J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD009923. DOI: 10.1002\/14651858.CD009923.pub2","DOI":"10.1002\/14651858.CD009923.pub2"},{"key":"876_CR5934","doi-asserted-by":"crossref","unstructured":"Meng Z, Yu J, Acuff M, et al. Tolerability of opioid analgesia for chronic pain: a network meta-analysis. Sci Rep 2017; 7:1995.","DOI":"10.1038\/s41598-017-02209-x"},{"key":"876_CR5940","doi-asserted-by":"crossref","unstructured":"Hoffmann F, Icks A. Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen f\u00fcr die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen 2012; 74:291-297.","DOI":"10.1055\/s-0031-1275711"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-022-0876-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-022-0876-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-022-0876-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T23:17:50Z","timestamp":1650583070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-022-0876-1"}},"subtitle":["Versorgungsforschungsstudie auf Basis repr\u00e4sentativer Krankenkassendaten"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s15006-022-0876-1","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"22 April 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PD Dr. Kai-Uwe Kern war in den letzten drei Jahren als Berater\/Referent f\u00fcr Betapharm, Berlin Chemie, Bionorica, Boehringer Ingelheim, Cannamedical, Gr\u00fcnenthal, Lilly, Sanofi, Stadapharm und Teva t\u00e4tig. Tobias Vogelmann ist Anteilseigner und Angestellter der LinkCare GmbH, die in der Vergangenheit Honorare f\u00fcr Beratungen und Forschungsunterst\u00fctzung von Indivior, STADAPHARM und Gr\u00fcnenthal erhielt. Prof. Thomas T\u00f6lle berichtet pers\u00f6nliche Honorare von AOP Orphan Almiral Hermal, Bionest Partner, Gr\u00fcnenthal, Hexal, Reckitt Benckiser \/Indivior, Kaia Health, Lilly, Medscape, Mundipharma, MSD, Novartis, Pfizer, Recordati Pharma, Sanofi-Aventis, TAD Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Diese Studie wurde von der Gr\u00fcnenthal GmbH, Aachen unterst\u00fctzt. Die Autoren danken Elke Grosselindemann und Birgit Brett f\u00fcr die redaktionelle Bearbeitung des Manuskripts. Alle Kosten im Zusammenhang mit der Erstellung des vorliegenden Manuskripts wurden von der Gr\u00fcnenthal GmbH, Aachen \u00fcbernommen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}